Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial

In the Japan Dialysis Active Vitamin D (J-DAVID) trial, oral alfacalcidol numerically, but not significantly, increased the risk of cardiovascular events among patients undergoing hemodialysis. Because the cardiovascular effect of alfacalcidol could be modulated by bone turnover status, this post-ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Tatsufumi, Sakaguchi, Yusuke, Isaka, Yoshitaka, Ishii, Haruka, Kabata, Daijiro, Shintani, Ayumi, Nakatani, Shinya, Morioka, Tomoaki, Mori, Katsuhito, Inaba, Masaaki, Emoto, Masanori, Shoji, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475027/
https://www.ncbi.nlm.nih.gov/pubmed/36104443
http://dx.doi.org/10.1038/s41598-022-19820-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475027/
https://www.ncbi.nlm.nih.gov/pubmed/36104443
http://dx.doi.org/10.1038/s41598-022-19820-2

Ejemplares similares